Technical Analysis for ACHN - Achillion Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 3.93 -1.50% -0.06
ACHN closed down 1.5 percent on Friday, September 13, 2019, on 55 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Flat Down
See historical ACHN trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
Down 3 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Centerline Cross Bearish -1.50%
NR7 Range Contraction -1.50%
Oversold Stochastic Weakness -1.50%
Oversold Stochastic Weakness -4.15%
Hammer Candlestick Bullish -5.53%
Lizard Bullish Bullish Day Trade Setup -5.53%

Older signals for ACHN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on the development of antivirals for the treatment of chronic hepatitis C viral (HCV) infection. The company's drug candidates for treating chronic HCV infection comprise Sovaprevir, a NS3 protease inhibitor, which has completed a Phase IIa clinical trial; ACH-3102, a NS5A inhibitor that is in Phase IIa clinical trial; and ACH-2684, a NS3 protease inhibitor, which has completed Phase Ia and 1b clinical trials. Its pipeline of antibacterial product candidates includes ACH-702 for the treatment of dermatologic and ophthalmic infections; and ACH-2881 for the treatment of serious resistant bacterial infections, including methicillin-resistant staphylococcus aureus. The company was founded in 1998 and is headquartered in New Haven, Connecticut.
Chemistry Biopharmaceutical Chemical Compounds Organic Compounds Infection Cyclopropanes Antiviral Drug Drug Therapies HCV Carbamates Hepatitis C Virus Ns3 Ns5a Protease Inhibitor Sulfonamides
Is ACHN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.03
52 Week Low 1.29
Average Volume 1,680,531
200-Day Moving Average 2.9836
50-Day Moving Average 3.9478
20-Day Moving Average 4.356
10-Day Moving Average 4.183
Average True Range 0.242
ADX 26.52
+DI 15.2536
-DI 25.6647
Chandelier Exit (Long, 3 ATRs ) 4.274
Chandelier Exit (Short, 3 ATRs ) 4.536
Upper Bollinger Band 4.8148
Lower Bollinger Band 3.8972
Percent B (%b) 0.04
BandWidth 21.065197
MACD Line -0.031
MACD Signal Line 0.0579
MACD Histogram -0.0889
Fundamentals Value
Market Cap 537.47 Million
Num Shares 137 Million
EPS -0.50
Price-to-Earnings (P/E) Ratio -7.86
Price-to-Sales 33.83
Price-to-Book 1.40
PEG Ratio -0.32
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.25
Resistance 3 (R3) 4.24 4.13 4.19
Resistance 2 (R2) 4.13 4.05 4.13 4.17
Resistance 1 (R1) 4.03 4.00 3.98 4.04 4.16
Pivot Point 3.92 3.92 3.89 3.92 3.92
Support 1 (S1) 3.82 3.84 3.77 3.83 3.70
Support 2 (S2) 3.71 3.79 3.71 3.69
Support 3 (S3) 3.61 3.71 3.67
Support 4 (S4) 3.62